Management of obesity as a chronic disease: Nonpharmacologic, pharmacologic, and surgical options

被引:89
作者
Fujioka, K [1 ]
机构
[1] Scripps Clin, Nutr & Metab Res Ctr, San Diego, CA 92130 USA
来源
OBESITY RESEARCH | 2002年 / 10卷
关键词
diet; physical activity; behavioral modification; antiobesity drug; gastric bypass;
D O I
10.1038/oby.2002.204
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The successful management of obesity requires a long-term approach that is tailored to an individual's lifestyle and needs. Initial treatment should focus on lifestyle modifications-dietary interventions and increased physical activity-with behavioral modification strategies used adjunctively. Several antiobesity drugs are approved by the Food and Drug Administration for use in obese patients, as well as in overweight individuals with at least one obesity-related comorbidity. Most are approved only for short-term weight loss, but sibutramine and orlistat are approved for long-term weight loss and maintenance. In addition to weight reduction, in clinical trials these drugs provided beneficial actions on several cardiovascular risk factors. Several other drugs currently approved for other uses show promise in their ability to cause weight loss. Surgical options should be reserved for severely obese patients with significant medical comorbidities or physical conditions.
引用
收藏
页码:116S / 123S
页数:8
相关论文
共 61 条
[1]  
*ABB LAB, 2001, MER PRESCR INF
[2]   Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial [J].
Anderson, JW ;
Greenway, FL ;
Fujioka, K ;
Gadde, KM ;
McKenney, J ;
O'Neil, PM .
OBESITY RESEARCH, 2002, 10 (07) :633-641
[3]   Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine [J].
Apfelbaum, M ;
Vague, P ;
Ziegler, O ;
Hanotin, C ;
Thomas, F ;
Leutenegger, E .
AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) :179-184
[4]   Topiramate for binge-eating disorder [J].
Appolinario, JC ;
Coutinho, W ;
Fontenelle, L .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (06) :967-968
[5]  
ASTRUP A, 1992, INT J OBESITY, V16, P269
[6]  
Astrup A, 2001, INT J OBESITY, V25, pS46, DOI 10.1038/sj/ijo/0801698
[7]   Absence of cardiac valve dysfunction in obese patients treated with sibutramine [J].
Bach, DS ;
Rissanen, AM ;
Mendel, CM ;
Shepherd, G ;
Weinstein, SP ;
Kelly, F ;
Seaton, TB ;
Patel, B ;
Pekkarinen, TA ;
Armstrong, WF .
OBESITY RESEARCH, 1999, 7 (04) :363-369
[8]   Use of nonprescription weight loss products - Results from a multistate survey [J].
Blanck, HM ;
Khan, LK ;
Serdula, MK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (08) :930-935
[9]   An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial [J].
Boozer, CN ;
Nasser, JA ;
Heymsfield, SB ;
Wang, V ;
Chen, G ;
Solomon, JL .
INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (03) :316-324
[10]   Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial [J].
Boozer, CN ;
Daly, PA ;
Homel, P ;
Solomon, JL ;
Blanchard, D ;
Nasser, JA ;
Strauss, R ;
Meredith, T .
INTERNATIONAL JOURNAL OF OBESITY, 2002, 26 (05) :593-604